SG11201906644YA - Pparϒ agonist for the treatment of huntington's disease - Google Patents
Pparϒ agonist for the treatment of huntington's diseaseInfo
- Publication number
- SG11201906644YA SG11201906644YA SG11201906644YA SG11201906644YA SG11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- huntington
- pct
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447741P | 2017-01-18 | 2017-01-18 | |
| PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906644YA true SG11201906644YA (en) | 2019-08-27 |
Family
ID=62908392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906644YA SG11201906644YA (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190350918A1 (es) |
| EP (1) | EP3570841A4 (es) |
| JP (1) | JP2020505448A (es) |
| KR (1) | KR20190122664A (es) |
| CN (1) | CN110461330A (es) |
| AU (1) | AU2018210165A1 (es) |
| BR (1) | BR112019014529A2 (es) |
| CA (1) | CA3050104A1 (es) |
| EA (1) | EA201991716A1 (es) |
| IL (1) | IL268008A (es) |
| MX (1) | MX2019008535A (es) |
| SG (1) | SG11201906644YA (es) |
| WO (1) | WO2018136635A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 |
| BR112019020485A2 (pt) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | Agonista ppary para tratamento de paralisia supranuclear progressiva |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| JP2008515978A (ja) * | 2004-10-13 | 2008-05-15 | ユニバーシティ オブ コネチカット | カンナビネルジック脂質リガンド |
| WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| WO2010040055A2 (en) * | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
| EP3513790A1 (en) * | 2009-07-01 | 2019-07-24 | JDS Therapeutics, LLC | Chromium complexes as enhancers of brain glucose transporters |
| AR098832A1 (es) * | 2013-12-20 | 2016-06-15 | Teva Pharma | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington |
-
2018
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en active Pending
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Application Discontinuation
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en unknown
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en active Pending
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3570841A4 (en) | 2020-08-19 |
| EP3570841A1 (en) | 2019-11-27 |
| KR20190122664A (ko) | 2019-10-30 |
| BR112019014529A2 (pt) | 2020-02-27 |
| IL268008A (en) | 2019-09-26 |
| AU2018210165A1 (en) | 2019-08-01 |
| WO2018136635A1 (en) | 2018-07-26 |
| CN110461330A (zh) | 2019-11-15 |
| US20190350918A1 (en) | 2019-11-21 |
| JP2020505448A (ja) | 2020-02-20 |
| EA201991716A1 (ru) | 2020-02-04 |
| CA3050104A1 (en) | 2018-07-26 |
| MX2019008535A (es) | 2019-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201906373VA (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201811237WA (en) | Combination therapies | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901320WA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201807596YA (en) | Gitr antibodies, methods, and uses | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders |